Hämatologie 2010

Was ist neu?

• Hämostaseologie: Neue orale Antikoagulanzien.

• Myelodysplastisches Syndrom: Azacitidin verlängert das Überleben bei Hochrisiko-Fällen.

• Chronische lymphatische Leukämie: Erstmals verlängertes Gesamtüberleben belegt.

• Morbus Waldenström: Der internationale prognostische Score erlaubt eine Abschätzung des klinischen Verlaufs.

• Follikuläres Lymphom: Bendamustin als gut verträgliche Therapieoption.

• Aggressives Lymphom: Die Hochdosistherapie mit autologer Stammzelltransplantation zeigt keinen Vorteil in der Erstlinien-Therapie.

• Multiples Lymphom: Lenalidomid und niedrig-dosiertes Dexamethason in der Primärtherapie.

Literatur

• 1 Connolly S J, Ezekowitz M D, Yusuf S. et al . Dabigatran versus warfarin in patients with atrial fibrillation.  N Engl J Med. 2009;  361 1139-1151
• 2 Eichhorst B, Busch R, Stilgenbauer S. First-line therapy with fludarabine compared with chlorambucil does not result in a major benfit for elderly patients with advanced chronic lymphocytic leukemia.  Blood. 2009;  114 3382-3391
• 3 Fenaux P, Mufti G J, Hellström-Lindberg E. et al . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.  Lancet Oncol. 2009;  10 223-232
• 4 Hallek M, Fingerle-Fowson, Fink A -M. et al . First-line treatment wih Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international roup of investigators and the German CLL study group.  Blood. 2009;  114 223 (Abstract 535)
• 5 Hulin C, Facon T, Rodon P. et al . Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial.  J Clin Oncol. 2009;  27 3664-3670
• 6 Morel P, Duhamel A, Gobbi P. et al . International prognostic scoring system for Waldenström macroglobulinemia.  Blood. 2009;  119 4163-4170
• 7 Rajkumar S V, Jacobus S, Callander N S. et al . Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.  Lancet Oncol. 2010;  11 29-37
• 8 Robak T, Dmoszynska A, Solal-Céligny P. et al . Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia.  JCO. 2010;  28 1756-1765
• 9 Rummel M J, Niederle N, Maschmeyer G. et al . Bendamustin plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL.  Blood. 2009;  114 168 (Abstract 405)
• 10 San M iguel JF, Schlag R, Khuageva N K. et al, VISTA Trial Investigators . Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.  N Engl J Med. 2008;  359 906-17
• 11 Schmitz N, Nickelsen M, Ziepert M. et al . Aressive chemotherapy (CHOEP-14) and Rituximab or high-dose therapy (MegaCHOEP) and Rituximab for young, high-risk patients with aggressive B-cell lymphoma: results of the MegaCHOEP trial of the German high-grade non-Hodgkin Lymphoma study group (DSHNHL).  Blood. 2009;  114 168 (Abstract 404)
• 12 Schulman S, Kearon C, Kakkar A K. et al . Dabigatran versus warfarin in the treatment of acute venous thromboembolism.  N Engl J Med. 2009;  361 2342-2352